Oncology Analytics, Inc.
Funding rounds
3 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Apr 2020 | $25 M | No. 3 | $10 to $50 million | equity | SEC | |
| Oct 2018 | $21 M | No. 2 | $10 to $50 million | equity | SEC | |
| Jan 2016 | $8 M | No. 1 | $2 to $10 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Oncology Analytics, Inc. chose not to state its revenue in its newest notice of a funding round (May 2020).
SEC Form D · May 2020
The industry group it chose in its notices: Other Health Care.
SEC Form D · May 2020
That is all the official record says: Oncology Analytics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
No investor of Oncology Analytics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 7 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Marc J. Fishman | Executive officer | May 2020 |
| Rick J. Dean | Executive officer | May 2020 |
| Balbino J. Vazquez | Executive officer | Nov 2018 |
| Balbino Vazquez | Executive officer | Jan 2016 |
| Danielle Fishman | Executive officer | Jan 2016 |
| Marc Fishman | Executive officer | Jan 2016 |
| Robert Walton | Executive officer | Jan 2016 |
| Ann J. Lamont | Director | May 2020 |
| Marc J. Fishman | Director | May 2020 |
| Michael J. Liang | Director | May 2020 |
| Michael J. Weintraub | Director | May 2020 |
| Peter J. Bach | Director | May 2020 |
| Rick J. Dean | Director | May 2020 |
| Thomas J. Hawes | Director | May 2020 |
| Zeke J. Emanuel | Director | May 2020 |
| Balbino J. Vazquez | Director | Nov 2018 |
| Dipa J. Mehta | Director | Nov 2018 |
| Marc J. Lippman | Director | Nov 2018 |
| Nick J. Rosa | Director | Nov 2018 |
| Balbino Vazquez | Director | Jan 2016 |
| John Bradburn | Director | Jan 2016 |
| Marc Fishman | Director | Jan 2016 |
| Marc Lippman | Director | Jan 2016 |
| Michael Montijo | Director | Jan 2016 |
| Nick Rosa | Director | Jan 2016 |
| Thomas Hawes | Director | Jan 2016 |